Subtype
Male Reproductive System Carcinoma
CI-CAN-00003134Explore in graph →
451 active trials16 approved drugs20 evidence items
- NCIt
- C181196
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003134Explore in graph →
Clinical trials
1,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (190)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02601014 | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7(STARVE-PC) | completed | Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT02673151 | 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment | completed | Phase 2 / Phase 3 | 61 | Andrei IagaruOTHER |
| 1 |
| Jan 13, 2022 |
| clinicaltrials |
| NCT02849990 | A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jan 13, 2022 | clinicaltrials |
| NCT02711956 | A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Zenith EpigeneticsINDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT03712930 | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | terminated | Phase 2 | 13 | BeiGeneINDUSTRY | 4 | Nov 17, 2021 | clinicaltrials |
| NCT02280317 | Dose Finding Safety Study of VAL201 in Cancer Patients(VAL201-001) | completed | Phase 1 / Phase 2 | 12 | ValiRx PlcINDUSTRY | 0 | Nov 8, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT02565901 | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 28 | University of WashingtonOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT04050215 | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer | completed | Phase 2 | 937 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT04020094 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer(AtezoVax) | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT02346578 | Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. | completed | Phase 2 | 104 | Taro Iguchi, MD, PHDOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03305224 | The Combination Therapy With Ra-223 and Enzalutamide(CORE-OCU) | unknown | Phase 2 | 10 | Taro Iguchi, MD, PHDOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT02985021 | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies | terminated | Phase 2 | 2 | Seattle Institute for Biomedical and Clinical ResearchOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT01505868 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT01503229 | Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 32 | University of WashingtonOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT01540071 | Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer | completed | Phase 2 | 38 | Io TherapeuticsINDUSTRY | 1 | May 14, 2021 | clinicaltrials |
| NCT02987829 | Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 72 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Apr 23, 2021 | clinicaltrials |
| NCT04839055 | The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC(CoA-CRPC) | unknown | Phase 1 / Phase 2 | 50 | Jiangnan UniversityOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT01468532 | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT03042312 | Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy(RESIST-PC) | terminated | Phase 2 | 71 | EndocyteINDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT03943602 | Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)(CaboPen) | unknown | Phase 2 | 37 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT03261336 | Oral Calcitriol With Ketoconazole in CRPC | terminated | Phase 2 | 1 | Donald Trump, MDOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT03741712 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | terminated | Phase 1 / Phase 2 | 9 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03514836 | A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | SOTIO a.s.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02844582 | Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 2 | University of California, DavisOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT04585932 | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT01882985 | Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients | completed | Phase 2 | 14 | University of California, IrvineOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT02031328 | Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer(2STAR) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT01576172 | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 159 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2020 | clinicaltrials |
| NCT01498978 | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03515577 | Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery(PSMA vs AXUMIN) | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04586543 | Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma | unknown | Phase 2 | 110 | László MangelOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03570476 | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Sep 21, 2020 | clinicaltrials |
| NCT01637402 | A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer | completed | Phase 2 | 41 | Terence Friedlander, MDOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT02125357 | Sequencing Abiraterone and Enzalutamide in mCRPC | completed | Phase 2 | 202 | British Columbia Cancer AgencyOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT01859689 | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT04486937 | SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation(mCRPC) | unknown | Phase 1 / Phase 2 | 90 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jul 27, 2020 | clinicaltrials |
| NCT02168062 | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer | terminated | Phase 2 | 57 | University of California, San FranciscoOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT03506997 | Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer(PERSEUS1) | unknown | Phase 2 | 100 | Institute of Cancer Research, United KingdomOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03827473 | Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer(ACADEMIC) | terminated | Phase 2 | 1 | University of UtahOTHER | 1 | Jun 25, 2020 | clinicaltrials |
| NCT02691975 | A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 197 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 13, 2020 | clinicaltrials |
| NCT02541903 | Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma | terminated | Phase 2 | 8 | University of Alabama at BirminghamOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT01787331 | Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer | completed | Phase 2 | 21 | University of California, San FranciscoOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02429193 | Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA(BARRIER-P) | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT00937768 | Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | terminated | Phase 2 | 16 | Mayo ClinicOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00450749 | Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2019 | clinicaltrials |
| NCT04188587 | 177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 30 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT02091531 | Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients | completed | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT04148885 | A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 44 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Nov 4, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Feb 3, 2022source: clinicaltrials